168 related articles for article (PubMed ID: 35312769)
1. GPC1-Targeted Immunotoxins Inhibit Pancreatic Tumor Growth in Mice via Depletion of Short-lived GPC1 and Downregulation of Wnt Signaling.
Pan J; Li N; Renn A; Zhu H; Chen L; Shen M; Hall MD; Qian M; Pastan I; Ho M
Mol Cancer Ther; 2022 Jun; 21(6):960-973. PubMed ID: 35312769
[TBL] [Abstract][Full Text] [Related]
2. Engineered Anti-GPC3 Immunotoxin, HN3-ABD-T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention.
Fleming BD; Urban DJ; Hall MD; Longerich T; Greten TF; Pastan I; Ho M
Hepatology; 2020 May; 71(5):1696-1711. PubMed ID: 31520528
[TBL] [Abstract][Full Text] [Related]
3. A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma.
Munekage E; Serada S; Tsujii S; Yokota K; Kiuchi K; Tominaga K; Fujimoto M; Kanda M; Uemura S; Namikawa T; Nomura T; Murakami I; Hanazaki K; Naka T
Neoplasia; 2021 Sep; 23(9):939-950. PubMed ID: 34332450
[TBL] [Abstract][Full Text] [Related]
4. Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis.
Gao W; Tang Z; Zhang YF; Feng M; Qian M; Dimitrov DS; Ho M
Nat Commun; 2015 Mar; 6():6536. PubMed ID: 25758784
[TBL] [Abstract][Full Text] [Related]
5. Fusion of an albumin-binding domain extends the half-life of immunotoxins.
Guo R; Guo W; Cao L; Liu H; Liu J; Xu H; Huang W; Wang F; Hong Z
Int J Pharm; 2016 Sep; 511(1):538-549. PubMed ID: 27457423
[TBL] [Abstract][Full Text] [Related]
6. Correlation of glypican-1 expression with TGF-beta, BMP, and activin receptors in pancreatic ductal adenocarcinoma.
Kayed H; Kleeff J; Keleg S; Jiang X; Penzel R; Giese T; Zentgraf H; Büchler MW; Korc M; Friess H
Int J Oncol; 2006 Nov; 29(5):1139-48. PubMed ID: 17016645
[TBL] [Abstract][Full Text] [Related]
7. A novel complement-fixing IgM antibody targeting GPC1 as a useful immunotherapeutic strategy for the treatment of pancreatic ductal adenocarcinoma.
Busato D; Capolla S; Durigutto P; Mossenta M; Bozzer S; Sblattero D; Macor P; Dal Bo M; Toffoli G
J Transl Med; 2023 Nov; 21(1):864. PubMed ID: 38017492
[TBL] [Abstract][Full Text] [Related]
8. Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma.
Li N; Fu H; Hewitt SM; Dimitrov DS; Ho M
Proc Natl Acad Sci U S A; 2017 Aug; 114(32):E6623-E6631. PubMed ID: 28739923
[TBL] [Abstract][Full Text] [Related]
9. Development of Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer: An Update.
Fleming BD; Ho M
Biomolecules; 2020 Jun; 10(6):. PubMed ID: 32575752
[TBL] [Abstract][Full Text] [Related]
10. Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer.
Fleming BD; Ho M
Toxins (Basel); 2016 Sep; 8(10):. PubMed ID: 27669301
[TBL] [Abstract][Full Text] [Related]
11. Glypican-1 Is a Novel Target for Stroma and Tumor Cell Dual-Targeting Antibody-Drug Conjugates in Pancreatic Cancer.
Tsujii S; Serada S; Fujimoto M; Uemura S; Namikawa T; Nomura T; Murakami I; Hanazaki K; Naka T
Mol Cancer Ther; 2021 Dec; 20(12):2495-2505. PubMed ID: 34583978
[TBL] [Abstract][Full Text] [Related]
12. Glypican-1 modulates the angiogenic and metastatic potential of human and mouse cancer cells.
Aikawa T; Whipple CA; Lopez ME; Gunn J; Young A; Lander AD; Korc M
J Clin Invest; 2008 Jan; 118(1):89-99. PubMed ID: 18064304
[TBL] [Abstract][Full Text] [Related]
13. The Glypican proteoglycans show intrinsic interactions with Wnt-3a in human prostate cancer cells that are not always associated with cascade activation.
de Moraes GFA; Listik E; Justo GZ; Vicente CM; Toma L
BMC Mol Cell Biol; 2021 May; 22(1):26. PubMed ID: 33947326
[TBL] [Abstract][Full Text] [Related]
14. Oridonin-loaded and GPC1-targeted gold nanoparticles for multimodal imaging and therapy in pancreatic cancer.
Qiu W; Chen R; Chen X; Zhang H; Song L; Cui W; Zhang J; Ye D; Zhang Y; Wang Z
Int J Nanomedicine; 2018; 13():6809-6827. PubMed ID: 30425490
[TBL] [Abstract][Full Text] [Related]
15. Glypican-1-targeted antibody-drug conjugate inhibits the growth of glypican-1-positive glioblastoma.
Uchida S; Serada S; Suzuki Y; Funajima E; Kitakami K; Dobashi K; Tamatani S; Sato Y; Beppu T; Ogasawara K; Naka T
Neoplasia; 2024 Apr; 50():100982. PubMed ID: 38417223
[TBL] [Abstract][Full Text] [Related]
16. B3(Fab)-PE38M: a recombinant immunotoxin in which a mutant form of Pseudomonas exotoxin is fused to the Fab fragment of monoclonal antibody B3.
Choe M; Webber KO; Pastan I
Cancer Res; 1994 Jul; 54(13):3460-7. PubMed ID: 8012967
[TBL] [Abstract][Full Text] [Related]
17. Anti-glypican-1 antibody-drug conjugate exhibits potent preclinical antitumor activity against glypican-1 positive uterine cervical cancer.
Matsuzaki S; Serada S; Hiramatsu K; Nojima S; Matsuzaki S; Ueda Y; Ohkawara T; Mabuchi S; Fujimoto M; Morii E; Yoshino K; Kimura T; Naka T
Int J Cancer; 2018 Mar; 142(5):1056-1066. PubMed ID: 29055044
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment.
Reiter Y; Pai LH; Brinkmann U; Wang QC; Pastan I
Cancer Res; 1994 May; 54(10):2714-8. PubMed ID: 8168102
[TBL] [Abstract][Full Text] [Related]
19. Glypican-1 Promotes Tumorigenesis by Regulating the PTEN/Akt/β-Catenin Signaling Pathway in Esophageal Squamous Cell Carcinoma.
Li J; Chen Y; Zhan C; Zhu J; Weng S; Dong L; Liu T; Shen X
Dig Dis Sci; 2019 Jun; 64(6):1493-1502. PubMed ID: 30730015
[TBL] [Abstract][Full Text] [Related]
20. Elevated glypican-1 expression is associated with an unfavorable prognosis in pancreatic ductal adenocarcinoma.
Lu H; Niu F; Liu F; Gao J; Sun Y; Zhao X
Cancer Med; 2017 Jun; 6(6):1181-1191. PubMed ID: 28440066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]